Antifungal and Immunomodulating Activities of 1,4-Benzothiazine Azole Derivatives: Review

REFERENCES

• Diamond RD. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis 1991; 13: 480–6.
   PubMedGoogle Scholar
• Denning DW. Epidemiology and pathogenesis of sys-temic fungal infections in the immunocompromised host. J Antimicrob Chemother 1991; 28: 1–16.
   PubMed Web of Science ®Google Scholar
• Dutcher JD. The discovery and development of ampho-tericin B. Dis Chest 1968; 54: 296–8.
   PubMedGoogle Scholar
• Grunberg E, Titsworth EH, Bennett ME. Chemotherapeutic activity of 5-fluorocytosine. Antimicrob Agents Chemother 1963; 3: 566–8.
   Google Scholar
• Godefroi EF, Heeres J, Van Cutsem J, Janssen PA. The preparation and antimycotic properties of derivatives of 1-phenethylimidazole. J Med Chem 1969; 12: 784–91.
   PubMed Web of Science ®Google Scholar
• Heeres J, Bacloc, LI Van Cutsem J. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel tria-zol-3-ones. J Med Chem 1984; 27: 894–900.
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997; 53: 539–49.
   Google Scholar
• Fromtling RA. Overview of medically important antifun-gal azole derivatives. Clin Microbiol Rev 1998; 1: 187–219.
   Google Scholar
• Bossche HV,Marichal P. In Yamaguchi H, Kobayashi GS, Takahashi H: Recent Progress in Antifungal Chemotherapy. New York, Marcel Dekker 1992: 25.
   Google Scholar
• Richardson K, Cooper K, Marriott MS, Tarbit MK, Troke PF, Whittle PJ. Design and evaluation of a systemically active agent, fluconazole. Ann NY Acad Sci 1988; 544: 4–11.
   PubMedGoogle Scholar
• Matsumoto Y, Tsuzuki R, Matsuhisa A, et al. Novel potassium channel openers. Part 4: transformation of the 1,4-benzoxazine skeleton into 1,4-benzothiazine, 1,2,3,4-tetrahy-droquinoline, 1,2,3,4-tetrahydroquinoxaline, indoline, and 1,5-benzoxazepine. Bioorg Med Chem 2000; 8: 393–404.
   Google Scholar
• Hirasawa A, Haruno A, Matsuzaki T, Hashimoto K. Effects of a new antiarrhythmic drug, SD-3212, on canine ventricular arrhythmia models. Jpn Heart J 1992; 33: 851–61
   PubMedGoogle Scholar
• Kajino M, Mizuno K, Tawada H, Shibouta Y, Nishikawa K, Meguro K. Synthesis and biological activities of new 1,4-benzothiazine derivatives. Chem Pharm Bull (Tokyo) 1991; 39: 2888-95.
   Google Scholar
• Campiani G, Garofalo A, Fiorini I, et al. Pyrrolo[2,1-c1[1,41benzothiazines: synthesis, structure-activity relationships, molecular modeling studies, and cardiovascular activity. J Med Chem 1995; 38: 4393-410.
   Google Scholar
• Cecchetti V, Fravolini A, Fringuelli R, et al. Synthesis and I3-adrenergic blocking activity of oxipropanolamines of 3,4-dihydro-3-oxo-2H(1,4) benzothiazine. Ii Farmaco 1987; 1: 61–75.
   Google Scholar
• Cecchetti V, Fringuelli R, Schiaffella F, et al. Synthesis and P-adrenergic blocking activity of 1,4-benzothiazine oxime ethers. Eur J Med Chem 1989; 24: 479–84.
   Web of Science ®Google Scholar
• Schiaffella F, Fringuelli R, Cecchetti V, Fravolini A, Angeli P, Marucci G. Enantiomers of 8-(3-tert-butylamino-2-hydroxypropoxy)-3,4-dihydro-3-oxo-2H(1,4)benzothiazine: racemic resolution, chiral synthesis and biological activity. Ii Farmaco 1990; 45: 1299-1307.
   Google Scholar
• Okuyama K, Kiuchi S, Okamoto M, Narita H, Kudo Y. T-477, a novel Ca(2+) and Na(+) channel blocker, prevents veratridine-induced neuronal injury. Eur J Pharmacol 2000; 398: 209–16.
   PubMed Web of Science ®Google Scholar
• Shen XM, Zhang F, Dryhurst G. Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem Res Toxicol 1997; 10: 147–55.
   PubMed Web of Science ®Google Scholar
• Shen XM, Dryhurst G. Oxidation chemistry of (-)nore-pinefrine in the presence of L-cysteine. J Med Chem 1996; 39: 2018–19.
   PubMed Web of Science ®Google Scholar
• Li H, Dryhurst G. Irreversible inhibition of mitochondri-al complex I by 7-(2-aminoethyll-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J Neurochem 1997; 69: 1530-41.
   Google Scholar
• Shen XM, Dryhurst G. Further insights into the influ-ence of L-cysteine on the oxidation chemistry of dopamine: reaction pathways of potential relevance to Parkinson's dis-ease. Chem Res Toxicol 1996; 9: 751–63.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Strobeck M, Schwartz A, Mori Y. Inhibitory effects of a new neuroprotective diltiazem analogue, T-477, on cloned brain Ca2+ channels expressed in Xenopus oocytes. Eur J Pharmacol 1997; 332: 313–20.
   PubMed Web of Science ®Google Scholar
• Li H, Shen XM, Dryhurst G. Brain mitochondria cat-alyze the oxidation of 7-(2-aminoethyll-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid (DHBT-1) to interme-diates that irreversibly inhibit complex I and scavenge glu-tathione: potential relevance to the pathogenesis of Parkinson's disease. J Neurochem 1998; 71: 2049-62.
   Google Scholar
• Coughlin SA, Danz DW, Robinson RG, et al. Mechanism of action and antitumor activity of (S)-10-(2,6-dimethy1-4-pyridiny1)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyridol[1,2,3-del[1,41benzothiazine-6-carboxylic acid (WIN 58161). Biochem Pharmacol 1995; 50: 111–22.
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Ito S, Inoue S, Wakamatsu K, Ozeki H, Ishiguro I. Dihydro-1,4-benzothiazine-6,7-dione, the ultimate toxic metabolite of 4-S-cysteaminylphenol and 4-5-cys-teaminylcatechol. Biochem Pharmacol 1997; 53: 1435-44.
   Google Scholar
• Inoue S, Hasegawa K, Wakamatsu K, Ito S. Comparison of antimelanoma effects of 4-S-cysteaminylphenol and its homologues. Melanoma Res 1998; 8: 105–12.
   PubMed Web of Science ®Google Scholar
• Baruffini A, Pagani G, Amoretti L. Derivatives of 1,4-benzothiazin-3-one. Ii Farmaco1967; 22: 528–34.
   PubMedGoogle Scholar
• Fringuelli R, Schiaffella F, Bistoni F, Pitzurra L, Vecchiarelli A. Azole derivatives of 1,4-benzothiazine as anti-fungal agents. Bioorg Med Chem 1998; 6: 103–8.
   PubMed Web of Science ®Google Scholar
• Schiaffella F, Guarraci A, Fringuelli R, Pitzurra L, Bistoni F, Vecchiarelli A. Synthesis and antifungal activity of new imidazole derivatives of 1,4-benzothiazine. Med Chem Res 1999; 9: 291–305.
   Web of Science ®Google Scholar
• Pitzurra L, Fringuelli R, Perito S, et al. A new azole derivative of 1,4-benzothiazine increases the antifungal mecha-nisms of natural effector cells. Antimicrob Agents Chemother 1999; 43: 2170–5.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa,1997.
   Google Scholar
• Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick VL. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994; 170: 384–9.
   PubMed Web of Science ®Google Scholar
• Rex JH, Galgiani JN, Bartlett MS, et al. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235–47.
   PubMed Web of Science ®Google Scholar
• Rex JH, Nelson PW, Paetzenick VL, Lozano-Chin M, Espaniel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129–34.
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A, Mazzolla R, Farinelli S, Cassone A, Bistoni F. Immunomodulation by Candida albicans: crucial role of organ colonization and chronic infection with an atten-uated agerminative strain of C. albicans for establishment of anti-infectious protection. J Gen Microbiol 1988; 134: 2583–92.
   Google Scholar
• Bistoni F, Vecchiarelli A, Mazzolla R, Puccetti P, Marconi P, Garaci E. Immunoadjuvant activity of amphotericin B as displayed in mice infected with Candida albicans. Antimicrob Agents Chemother 1985; 27: 625–31.
   PubMed Web of Science ®Google Scholar
• Romani L. Immunity to Candida albicans: Thl, Th2 cells and beyond. Curr Opin Microbiol 1999; 2: 363–7.
   PubMed Web of Science ®Google Scholar
• Vecchiarelli A, Pietrella D, Dottorini M, et al. Encapsulation of Ctyptococcus neoformans regulates fungici-dal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol 1994; 98: 217–23.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and interferon-gamma. Do they always go together? Am J Pathol 1995; 147: 1534–8.
   PubMed Web of Science ®Google Scholar
• Paulnock DM, Demick KP, Goner SP. Analysis of inter-feron-gamma-dependent and -independent pathways of macrophage activation. J Leukoc Biol 2000; 67: 677–82.
   PubMed Web of Science ®Google Scholar